- Home
- NBY vs ZVSA Comparison
NBY vs ZVSA Comparison
Compare NBY & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- ZVSA
- Stock Information
- Founded
- NBY 2000
- ZVSA 2014
- Country
- NBY United States
- ZVSA United States
- Employees
- NBY N/A
- ZVSA N/A
- Industry
- NBY
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- ZVSA Health Care
- Exchange
- NBY Nasdaq
- ZVSA Nasdaq
- Market Cap
- NBY 3.5M
- ZVSA 3.0M
- IPO Year
- NBY 2007
- ZVSA N/A
- Fundamental
- Price
- NBY $0.60
- ZVSA $0.69
- Analyst Decision
- NBY Strong Buy
- ZVSA
- Analyst Count
- NBY 1
- ZVSA 0
- Target Price
- NBY $0.85
- ZVSA N/A
- AVG Volume (30 Days)
- NBY 32.1K
- ZVSA 1.5M
- Earning Date
- NBY 08-12-2025
- ZVSA 08-08-2025
- Dividend Yield
- NBY N/A
- ZVSA N/A
- EPS Growth
- NBY N/A
- ZVSA N/A
- EPS
- NBY 0.57
- ZVSA N/A
- Revenue
- NBY $9,781,000.00
- ZVSA N/A
- Revenue This Year
- NBY $23.91
- ZVSA N/A
- Revenue Next Year
- NBY $32.05
- ZVSA N/A
- P/E Ratio
- NBY $1.33
- ZVSA N/A
- Revenue Growth
- NBY 20.52
- ZVSA N/A
- 52 Week Low
- NBY $0.36
- ZVSA $0.47
- 52 Week High
- NBY $2.47
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- NBY 53.58
- ZVSA 53.43
- Support Level
- NBY $0.56
- ZVSA $0.61
- Resistance Level
- NBY $0.64
- ZVSA $0.73
- Average True Range (ATR)
- NBY 0.03
- ZVSA 0.07
- MACD
- NBY -0.00
- ZVSA 0.00
- Stochastic Oscillator
- NBY 44.44
- ZVSA 36.53
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.